BBIO · Categories · Coverage
BBIO - Analyst coverage initiated
BridgeBio Pharma Inc. (BBIO) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for BBIO
- Canaccord Genuity initiated coverage on BridgeBio Pharma with a new price targetCanaccord Genuity initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $104.00
- Citigroup initiated coverage on BridgeBio Pharma with a new price targetCitigroup initiated coverage of BridgeBio Pharma with a rating of Neutral and set a new price target of $82.00
- RBC Capital Mkts initiated coverage on BridgeBio Pharma with a new price targetRBC Capital Mkts initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $100.00
- William Blair initiated coverage on BridgeBio PharmaWilliam Blair initiated coverage of BridgeBio Pharma with a rating of Outperform
- Barclays initiated coverage on BridgeBio Pharma with a new price targetBarclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00
- Morgan Stanley initiated coverage on BridgeBio Pharma with a new price targetMorgan Stanley initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $96.00
- Bernstein initiated coverage on BridgeBio Pharma with a new price targetBernstein initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $94.00
- Truist initiated coverage on BridgeBio Pharma with a new price targetTruist initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $66.00
- Jefferies initiated coverage on BridgeBio Pharma with a new price targetJefferies initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $70.00
- Wolfe Research initiated coverage on BridgeBio Pharma with a new price targetWolfe Research initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $49.00
- Redburn Atlantic initiated coverage on BridgeBio Pharma with a new price targetRedburn Atlantic initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $50.00
- Scotiabank initiated coverage on BridgeBio PharmaScotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform
- Oppenheimer initiated coverage on BridgeBio PharmaOppenheimer initiated coverage of BridgeBio Pharma with a rating of Perform
- Piper Sandler initiated coverage on BridgeBio Pharma with a new price targetPiper Sandler initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $46.00
- BMO Capital Markets initiated coverage on BridgeBio Pharma with a new price targetBMO Capital Markets initiated coverage of BridgeBio Pharma with a rating of Market Perform and set a new price target of $37.00
- Wells Fargo initiated coverage on BridgeBio Pharma with a new price targetWells Fargo initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $58.00
- Wells Fargo initiated coverage on BridgeBio PharmaWells Fargo initiated coverage of BridgeBio Pharma with a rating of Overweight
- Citigroup initiated coverage on BridgeBio Pharma with a new price targetCitigroup initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $42.00
- Cantor Fitzgerald initiated coverage on BridgeBio Pharma with a new price targetCantor Fitzgerald initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $50.00
- Evercore ISI initiated coverage on BridgeBio Pharma with a new price targetEvercore ISI initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $40.00
- Cowen initiated coverage on BridgeBio PharmaCowen initiated coverage of BridgeBio Pharma with a rating of Outperform
- UBS initiated coverage on BridgeBio Pharma with a new price targetUBS initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $80.00
- JPMorgan Chase & Co. initiated coverage on BridgeBio PharmaJPMorgan Chase & Co. initiated coverage of BridgeBio Pharma with a rating of Overweight
- The Goldman Sachs Group initiated coverage on BridgeBio Pharma with a new price targetThe Goldman Sachs Group initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $83.00
- The Goldman Sachs Group initiated coverage on BridgeBio PharmaThe Goldman Sachs Group initiated coverage of BridgeBio Pharma with a rating of Buy